1.
|
SEC
Comment.
We note from your disclosure on page 5 that you lease your PCT Sample
Preparation System, which includes your Barocycler instrument and
your
single-use PULSE Tubes. Please tell us and revise your future filings
to
explain the nature of these agreements and to disclose your revenue
recognition policy associated with these lease agreements.
|
Company
Response.
|
2.
|
SEC
Comment.
We note here and on page 40 that you have capitalized inventory that
includes your PCT units that are used within your operations for
training
and demonstration purposes, your collaboration arrangements, and
are also
leased to customers. Please tell us and revise your future filings
to
address the following:
|
· |
Describe
the nature of the arrangements that you enter into and your accounting
policies related to this equipment under each type of
arrangement;
|
· |
Discuss
the basis at which transfer your equipment from inventory to plant,
property, and equipment;
|
· |
Describe
the contractual terms through which you loan the systems, including
the
typical term of the loan, any associated requirements that the borrower
purchase any disposable products or
services;
|
· |
Disclose
how you record amortization expense, how it is reflected in the financial
statements and why you believe the classification is
appropriate.
|
- |
Internal
use - placed in our own laboratories for use by our researchers.
These
instruments are capitalized as fixed assets and depreciated over
their
three year estimated useful life on a straight-line basis. The
depreciation expense is classified as “Research and development” in our
Consolidated Statements of Operations.
|
- |
Collaboration
program - placed in the laboratory of a third party researcher who
wishes
to experiment by applying our technology to their area of research.
These
agreements typically have a term of between 30 and 180 days. We incur
all
of the cost to install and maintain the instrument throughout the
term of
the agreement. While the third party researcher is not required to
pay for
the use of the Barocycler instrument, we typically negotiate a minimum
purchase of between $300 and $1,000 of our consumable PULSE Tubes
during
the term of these agreements. These Barocycler instruments are capitalized
as fixed assets and depreciated over their three year estimated useful
life on a straight-line basis. The depreciation expense is classified
as
“Research and development” in our Consolidated Statements of Operations.
|
- |
Lease
agreement - please refer to the Company response to SEC Comment
1.
|
- |
Sale
agreement - In a few cases, our collaborators purchased our
instrumentation at the end of their collaboration agreement. In these
cases, we transferred the assets sold from fixed assets to inventory
and
then expensed the inventory through “Cost of PCT products & services”
in our Consolidated Statements of Operations. These transfers from
fixed
assets to inventory were recorded at net book value at the time of
transfer.
|
3.
|
SEC
Comment.
We note that you do not make an estimate of forfeitures in valuing
your
stock options granted since you are in the early stages of development
as
a new company and you have a limited workforce of fourteen employees.
Please revise future filings to include an estimate of forfeitures
as
required by SFAS 123(R). Refer to the guidance in paragraphs 43 and
B166
of SFAS 123(R).
|
Company
Response.
Future filings will be revised to comply with the staff’s
comment.
|
4.
|
SEC
Comment.
Please tell us and revise future filings to disclose the amounts
of
related party transactions for each of the periods for which you
present
your consolidated statements of operations. Please also disclose
the
amounts due to or from the Source Scientific as of the balance sheet
date
and the terms and manner of settlement. Refer to paragraph 2(c) and
2(d)
of SFAS 57.
|
Company
Response.
|
5.
|
SEC
Comment.
We note your disclosure that your management, including [your] principal
executive officer and principal financial officer, “concluded [your]
disclosure controls and procedures are effective in enabling [you]
to
record, process, summarize and report information required to be
included
in [your] periodic SEC filings within the required time periods.” Revise
future filings to clarify, if true, that your officers concluded
that your
disclosure controls and procedures are also effective to ensure that
information required to be disclosed in the reports that you file
or
submit under the Exchange Act is accumulated and communicated to
your
management, including your chief financial officer, to allow timely
decisions regarding required disclosure. See Exchange Act Rule
13a-15(e).
|
6.
|
SEC
Comment.
We note that the certifications filed pursuant to Exchange Act Rule
13a-14(a) are not in the exact form prescribed by Item 601(b)(31)
of
Regulation S-B. Specifically, we note that you improperly include
the
title of the certifying official in the introduction of your
certification. Please revise your certifications in future filings
to
conform to the exact wording required by Item 601(b)(31) of Regulation
S-B.
|